Skip to main content
Back
SHJBF logo

Shanghai Junshi Biosciences Co., Ltd.

Data quality: 100%
Overbought
SHJBF
OTC Healthcare Biotechnology
$3.00
$0.00 (0.00%)
Mkt Cap: 4.34B
Day Range
$3.00 $3.00
52-Week Range
$1.97 $4.23
Volume
1,000
50D / 200D Avg
$3.00 / $2.99
Prev Close
$3.00

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E -5.1 0.4
P/B 0.7 2.9
ROE % -14.3 3.8
Net Margin % -35.0 3.9
Rev Growth 5Y % -11.8 10.0
D/E 0.7 0.2

Analyst Price Target

No analyst coverage available

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2028 -$0.12
-$0.13 – -$0.12
5.2 B 1
FY2027 -$0.22
-$0.23 – -$0.21
4.1 B 1
FY2026 -$0.52
-$0.54 – -$0.50
3.3 B 1

Key Takeaways

Revenue declined -11.82% annually over 5 years
Negative free cash flow of -1.21B
PEG of 0.72 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 36.75%
Capital intensive — 30.75% of revenue goes to capex

Growth

Revenue Growth (5Y)
-11.82%
Revenue (1Y)24.93%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-14.30%
ROIC-6.70%
Net Margin-35.00%
Op. Margin-37.37%

Safety

Debt / Equity
0.69
Current Ratio1.60
Interest Coverage-12.37

Valuation

P/E Ratio
-5.09
P/B Ratio0.72
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 24.93% Revenue Growth (3Y) 27.27%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -11.82% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 2.43B Net Income (TTM) -851.83M
ROE -14.30% ROA -6.88%
Gross Margin 72.34% Operating Margin -37.37%
Net Margin -35.00% Free Cash Flow (TTM) -1.21B
ROIC -6.70% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.69 Current Ratio 1.60
Interest Coverage -12.37 Dividend Yield 0.00%
Valuation
P/E Ratio -5.09 P/B Ratio 0.72
P/S Ratio 1.78 PEG Ratio 0.72
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 4.34B Enterprise Value 5.86B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 2.43B 1.95B 1.50B 1.45B 4.02B
Net Income -851.83M -1.28B -2.28B -2.39B -718.56M
EPS (Diluted) -0.84 -1.30 -2.32 -2.60 -0.81
Gross Profit 1.76B 1.45B 835.26M 927.21M 2.77B
Operating Income -909.47M -1.30B -2.45B -2.75B -592.71M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 12.39B 10.80B 11.36B 12.56B 11.05B
Total Liabilities 6.16B 4.85B 4.02B 2.78B 2.72B
Shareholders' Equity 6.03B 5.88B 7.17B 9.48B 7.96B
Total Debt 4.14B 2.93B 1.79B 1.32B 628.20M
Cash & Equivalents 2.62B 2.49B 3.78B 6.00B 3.50B
Current Assets 4.46B 4.28B 5.55B 7.22B 5.83B
Current Liabilities 2.78B 2.53B 2.48B 1.77B 2.02B